<?xml version='1.0' encoding='utf-8'?>
<document id="24691799"><sentence text="Pharmacokinetic interaction between simvastatin and fenofibrate with staggered and simultaneous dosing: Does it matter?"><entity charOffset="36-47" id="DDI-PubMed.24691799.s1.e0" text="simvastatin" /><entity charOffset="52-63" id="DDI-PubMed.24691799.s1.e1" text="fenofibrate" /><pair ddi="false" e1="DDI-PubMed.24691799.s1.e0" e2="DDI-PubMed.24691799.s1.e0" /><pair ddi="false" e1="DDI-PubMed.24691799.s1.e0" e2="DDI-PubMed.24691799.s1.e1" /></sentence><sentence text="Simvastatin and fenofibrate are frequently co-prescribed at staggered intervals for the treatment of dyslipidemia"><entity charOffset="0-11" id="DDI-PubMed.24691799.s2.e0" text="Simvastatin" /><entity charOffset="16-27" id="DDI-PubMed.24691799.s2.e1" text="fenofibrate" /><pair ddi="false" e1="DDI-PubMed.24691799.s2.e0" e2="DDI-PubMed.24691799.s2.e0" /><pair ddi="false" e1="DDI-PubMed.24691799.s2.e0" e2="DDI-PubMed.24691799.s2.e1" /></sentence><sentence text=" Since a drug-drug interaction has been reported when the two drugs are given simultaneously, it is of clinical interest to know whether the interaction differs between simultaneous and staggered combinations" /><sentence text=" A study, assessing the impact of both combinations on the interaction, was conducted with 7-day treatment regimens using simvastatin 40 mg and fenofibrate 145 mg: (A) simvastatin only (evening), (B) simvastatin and fenofibrate (both in evening), and (C) simvastatin (evening) and fenofibrate (morning)"><entity charOffset="122-133" id="DDI-PubMed.24691799.s4.e0" text="simvastatin" /><entity charOffset="144-155" id="DDI-PubMed.24691799.s4.e1" text="fenofibrate" /><entity charOffset="168-179" id="DDI-PubMed.24691799.s4.e2" text="simvastatin" /><entity charOffset="200-211" id="DDI-PubMed.24691799.s4.e3" text="simvastatin" /><entity charOffset="216-227" id="DDI-PubMed.24691799.s4.e4" text="fenofibrate" /><entity charOffset="255-266" id="DDI-PubMed.24691799.s4.e5" text="simvastatin" /><entity charOffset="281-292" id="DDI-PubMed.24691799.s4.e6" text="fenofibrate" /><pair ddi="false" e1="DDI-PubMed.24691799.s4.e0" e2="DDI-PubMed.24691799.s4.e0" /><pair ddi="false" e1="DDI-PubMed.24691799.s4.e0" e2="DDI-PubMed.24691799.s4.e1" /><pair ddi="false" e1="DDI-PubMed.24691799.s4.e0" e2="DDI-PubMed.24691799.s4.e2" /><pair ddi="false" e1="DDI-PubMed.24691799.s4.e0" e2="DDI-PubMed.24691799.s4.e3" /><pair ddi="false" e1="DDI-PubMed.24691799.s4.e0" e2="DDI-PubMed.24691799.s4.e4" /><pair ddi="false" e1="DDI-PubMed.24691799.s4.e0" e2="DDI-PubMed.24691799.s4.e5" /><pair ddi="false" e1="DDI-PubMed.24691799.s4.e0" e2="DDI-PubMed.24691799.s4.e6" /><pair ddi="false" e1="DDI-PubMed.24691799.s4.e1" e2="DDI-PubMed.24691799.s4.e1" /><pair ddi="false" e1="DDI-PubMed.24691799.s4.e1" e2="DDI-PubMed.24691799.s4.e2" /><pair ddi="false" e1="DDI-PubMed.24691799.s4.e1" e2="DDI-PubMed.24691799.s4.e3" /><pair ddi="false" e1="DDI-PubMed.24691799.s4.e1" e2="DDI-PubMed.24691799.s4.e4" /><pair ddi="false" e1="DDI-PubMed.24691799.s4.e1" e2="DDI-PubMed.24691799.s4.e5" /><pair ddi="false" e1="DDI-PubMed.24691799.s4.e1" e2="DDI-PubMed.24691799.s4.e6" /><pair ddi="false" e1="DDI-PubMed.24691799.s4.e2" e2="DDI-PubMed.24691799.s4.e2" /><pair ddi="false" e1="DDI-PubMed.24691799.s4.e2" e2="DDI-PubMed.24691799.s4.e3" /><pair ddi="false" e1="DDI-PubMed.24691799.s4.e2" e2="DDI-PubMed.24691799.s4.e4" /><pair ddi="false" e1="DDI-PubMed.24691799.s4.e2" e2="DDI-PubMed.24691799.s4.e5" /><pair ddi="false" e1="DDI-PubMed.24691799.s4.e2" e2="DDI-PubMed.24691799.s4.e6" /><pair ddi="false" e1="DDI-PubMed.24691799.s4.e3" e2="DDI-PubMed.24691799.s4.e3" /><pair ddi="false" e1="DDI-PubMed.24691799.s4.e3" e2="DDI-PubMed.24691799.s4.e4" /><pair ddi="false" e1="DDI-PubMed.24691799.s4.e3" e2="DDI-PubMed.24691799.s4.e5" /><pair ddi="false" e1="DDI-PubMed.24691799.s4.e3" e2="DDI-PubMed.24691799.s4.e6" /><pair ddi="false" e1="DDI-PubMed.24691799.s4.e4" e2="DDI-PubMed.24691799.s4.e4" /><pair ddi="false" e1="DDI-PubMed.24691799.s4.e4" e2="DDI-PubMed.24691799.s4.e5" /><pair ddi="false" e1="DDI-PubMed.24691799.s4.e4" e2="DDI-PubMed.24691799.s4.e6" /><pair ddi="false" e1="DDI-PubMed.24691799.s4.e5" e2="DDI-PubMed.24691799.s4.e5" /><pair ddi="false" e1="DDI-PubMed.24691799.s4.e5" e2="DDI-PubMed.24691799.s4.e6" /></sentence><sentence text=" Eighty-five healthy subjects received the respective treatments in a randomized, 3-way cross-over study" /><sentence text=" The pharmacokinetics of simvastatin and the active metabolite simvastatin acid were determined"><entity charOffset="25-36" id="DDI-PubMed.24691799.s6.e0" text="simvastatin" /><entity charOffset="63-79" id="DDI-PubMed.24691799.s6.e1" text="simvastatin acid" /><pair ddi="false" e1="DDI-PubMed.24691799.s6.e0" e2="DDI-PubMed.24691799.s6.e0" /><pair ddi="false" e1="DDI-PubMed.24691799.s6.e0" e2="DDI-PubMed.24691799.s6.e1" /></sentence><sentence text=" There was a limited reduction in the AUC0-24h of simvastatin acid of 21 and 29% for simultaneous and staggered combination, respectively"><entity charOffset="50-66" id="DDI-PubMed.24691799.s7.e0" text="simvastatin acid" /></sentence><sentence text=" The geometric mean AUC0-24h ratio of simvastatin acid for the two combined dosing regimens (B/C) and 90% confidence interval were 111% (102-121)"><entity charOffset="38-54" id="DDI-PubMed.24691799.s8.e0" text="simvastatin acid" /></sentence><sentence text=" The interaction apparently had no impact on lipid markers" /><sentence text=" The findings imply that the observed pharmacokinetic interaction is unlikely clinically relevant, and support the combined use of simvastatin and fenofibrate not only given at staggered interval but also given simultaneously"><entity charOffset="131-142" id="DDI-PubMed.24691799.s10.e0" text="simvastatin" /><entity charOffset="147-158" id="DDI-PubMed.24691799.s10.e1" text="fenofibrate" /><pair ddi="false" e1="DDI-PubMed.24691799.s10.e0" e2="DDI-PubMed.24691799.s10.e0" /><pair ddi="false" e1="DDI-PubMed.24691799.s10.e0" e2="DDI-PubMed.24691799.s10.e1" /></sentence><sentence text=" " /></document>